small molecule

TYRVAYA

VARENICLINE TARTRATE

Loss of exclusivityOctober 2035latest FDA-listed patent expiry

CompanyOyster Point Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand name	TYRVAYA
Active ingredient	VARENICLINE TARTRATE
Strength	EQ 0.03MG BASE/SPRAY
Dosage form	SPRAY
Route	NASAL
Modality	Small molecule
FDA approval	October 2021
Marketing status	RX

Listed patents

Patent	Expires	Type
11224598	October 2035	use U-1900
10456396	October 2035	product
9597284	October 2035	use U-1900
9532944	October 2035	use U-1900
9504644	October 2035	use U-1900
11911380	October 2035	use U-1900
11903943	October 2035	use U-1900
11903941	October 2035	use U-1900
12576080	October 2035	use U-1900
12653824	October 2035	product
9504645	October 2035	product
11903942	October 2035	product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.